In CVD-free individuals, risk of diabetes increases with elevated blood pressure
7-10-2015 • Emdin CA et al., J Am Coll Cardiol. 2015
Risk of new onset diabetes increased with higher SBP and DBP. Relative risk increase was lower in older people and those with BMI>35, but absolute risk remained substantial in those individuals.
News • 29-9-2015 • Prague, Sept 17-18, 2015
Lively debate at annual EPCCS Clinical Masterclass to yield practical guidance
This year’s EPCCS Meeting dedicated much time to discussion and identifying gaps in the evidence, aimed at composing practical recommendations for CV risk management in general practice.
The role of nonstatin lipid-modifying agents in CV risk management
28-9-2015 • Hegele RA et al., ATVB 2015
Recent data show that similar CV benefits can be achieved with nonstatin agents, as with statins, suggesting that pleiotropic effects of statins are not central to their effects.
News • 7-9-2015
New heart failure agent also beneficial at systolic hypertension and arterial stiffness
LCZ696 lowers central blood pressure and pulse pressure more effectively than an angiotensin receptor blocker in a high-risk population with systolic hypertension and increased pulse pressure.
News • 5-9-2015
Spironolactone most effective treatment for resistant hypertension
In patients with resistant hypertension, addition of the diuretic spironolactone was significantly more effective than adding other BP-lowering drugs, according to results of the PATHWAY-2 trial.
Self-injectable PCSK9 antibody well accepted by patients and prescribers
24-8-2015 • Roth EM et al., Clin Ther. 2015
Willingness of patients to self-inject and of physicians to prescribe alirocumab using a prefilled pen or syringe was high. Specialists estimated acceptance by patients higher than primary care physicians.
Risk prediction with SCORE model not improved by addition HDL-C
6-10-2015 • Mortensen MB et al., Eur Heart J 2015
The newly recommended SCORE-HDL model did not improve discrimination between cases and non-cases in a ‘low-risk’ country, and both models overestimate risk of fatal CVD in this population.
News • 28-9-2015
Next step on the way to approval of first antidote to anticoagulant effect of NOAC
Following accelerated assessment, EMAs CHMP recommends granting a marketing authorisation for idarucizumab, a reversal agent for dabigatran, given its potential to respond to an unmet medical need.
Glucose-lowering agent shows CV benefit in outcome trial, for the first time
21-9-2015 • Zinman B et al., NEJM 2015
Treatment with SGLT2 inhibitor empagliflozin in addition to standard care reduces CV mortality, nonfatal MI and stroke in T2DM patients at high CV risk, shows the EMPA-REG OUTCOME trial.
News • 7-9-2015
Using two common diuretics at half dose is effective without undesired side effects
The combination of amiloride and hydrochlorothiazide, each at half dose, can significantly reduce BP without the side-effects caused by full doses of either alone, the PATHWAY 3 study showed.
News • 26-8-2015
E-health vital to beat CV disease, says ESC
European Society of Cardiology position paper outlines how the ESC will exploit e-health, the use of ICT in healthcare services, in education and research, while tackling issues of quality control and data security.
More CV health risks with industrial trans fats than with saturated fats
23-8-2015 • De Souza RJ et al., BMJ 2015
Meta-analysis of the association between fat intake and CV health reports higher CV morbidity and mortality with increased trans fat intake (mostly industrially produced), but not with saturated fats.
All upcoming meetings...
Meeting reports & resources
EPCCS Guidance Documents
Evidence- and meeting-based guidance for primary care
Report of 8th Annual EPCCS meeting held in Prague.
Report of 7th Annual EPCCS meeting held in Brussels.
Report of 6th Annual EPCCS meeting held in London
All meeting reports...